Neale, J., Parkin, S., & Strang, J. (2023). ‘Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors’, Drugs, Education, Prevention and Policy.

Joanne Neale; Stephen Parkin; John Strang

Neale, J., Parkin, S., & Strang, J. (2023). ‘Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors’, Drugs, Education, Prevention and Policy.

Joanne Neale, Stephen Parkin, John Strang

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Depot buprenorphine can potentially address many limitations of other forms of opioid replacement therapy (ORT). This paper builds upon the concept of the ‘informed patient’ to explore individuals’ decisions to initiate injectable depot buprenorphine. Methods: Data derive from a qualitative study of 26 people with opioid use disorder who were recruited from drug treatment services in England and Wales and interviewed within 72 hours of starting injectable depot buprenorphine treatment. Interviews were conducted by telephone, audio-recorded, transcribed verbatim, and analysed via Iterative Categorization. Findings: Participants’ decisions to initiate treatment were underpinned by receiving sufficient information to trust depot buprenorphine; current treatment not meeting their personal needs or goals; frequently uncritical perceptions of depot buprenorphine; and restricted access to depot buprenorphine making recipients feel grateful. Overall, participants said they had enough information and knowledge to decide they wanted depot buprenorphine. However, dissatisfaction with current ORT, desire for better treatment, and depot buprenorphine’s limited availability seemed to hinder informed decision-making. Conclusions: Whilst pharmaceutical products cannot solve the complex life problems often associated with opioid use disorder, we need to increase access to all ORT forms so that patients do not feel they have to rush into any medication without adequate preparation.

Original language	English
Journal	Drugs: Education, Prevention and Policy
Publication status	Published - 2 Jan 2023

Fingerprint

Dive into the research topics of 'Neale, J., Parkin, S., & Strang, J. (2023). ‘Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors’, Drugs, Education, Prevention and Policy.'. Together they form a unique fingerprint.

Cite this

@article{d556d3e69bf549ce8db3ff55f7405268,

title = "Neale, J., Parkin, S., & Strang, J. (2023). {\textquoteleft}Qualitative study of patients{\textquoteright} decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors{\textquoteright}, Drugs, Education, Prevention and Policy.",

abstract = "Background: Depot buprenorphine can potentially address many limitations of other forms of opioid replacement therapy (ORT). This paper builds upon the concept of the {\textquoteleft}informed patient{\textquoteright} to explore individuals{\textquoteright} decisions to initiate injectable depot buprenorphine. Methods: Data derive from a qualitative study of 26 people with opioid use disorder who were recruited from drug treatment services in England and Wales and interviewed within 72 hours of starting injectable depot buprenorphine treatment. Interviews were conducted by telephone, audio-recorded, transcribed verbatim, and analysed via Iterative Categorization. Findings: Participants{\textquoteright} decisions to initiate treatment were underpinned by receiving sufficient information to trust depot buprenorphine; current treatment not meeting their personal needs or goals; frequently uncritical perceptions of depot buprenorphine; and restricted access to depot buprenorphine making recipients feel grateful. Overall, participants said they had enough information and knowledge to decide they wanted depot buprenorphine. However, dissatisfaction with current ORT, desire for better treatment, and depot buprenorphine{\textquoteright}s limited availability seemed to hinder informed decision-making. Conclusions: Whilst pharmaceutical products cannot solve the complex life problems often associated with opioid use disorder, we need to increase access to all ORT forms so that patients do not feel they have to rush into any medication without adequate preparation.",

author = "Joanne Neale and Stephen Parkin and John Strang",

year = "2023",

month = jan,

day = "2",

language = "English",

journal = "Drugs: Education, Prevention and Policy",

issn = "0968-7637",

publisher = "Taylor and Francis",

}

Neale, J., Parkin, S., & Strang, J. (2023). ‘Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors’, Drugs, Education, Prevention and Policy. / Neale, Joanne ; Parkin, Stephen ; Strang, John.
In: Drugs: Education, Prevention and Policy, 02.01.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Neale, J., Parkin, S., & Strang, J. (2023). ‘Qualitative study of patients’ decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors’, Drugs, Education, Prevention and Policy.

AU - Neale, Joanne

AU - Parkin, Stephen

AU - Strang, John

PY - 2023/1/2

Y1 - 2023/1/2

N2 - Background: Depot buprenorphine can potentially address many limitations of other forms of opioid replacement therapy (ORT). This paper builds upon the concept of the ‘informed patient’ to explore individuals’ decisions to initiate injectable depot buprenorphine. Methods: Data derive from a qualitative study of 26 people with opioid use disorder who were recruited from drug treatment services in England and Wales and interviewed within 72 hours of starting injectable depot buprenorphine treatment. Interviews were conducted by telephone, audio-recorded, transcribed verbatim, and analysed via Iterative Categorization. Findings: Participants’ decisions to initiate treatment were underpinned by receiving sufficient information to trust depot buprenorphine; current treatment not meeting their personal needs or goals; frequently uncritical perceptions of depot buprenorphine; and restricted access to depot buprenorphine making recipients feel grateful. Overall, participants said they had enough information and knowledge to decide they wanted depot buprenorphine. However, dissatisfaction with current ORT, desire for better treatment, and depot buprenorphine’s limited availability seemed to hinder informed decision-making. Conclusions: Whilst pharmaceutical products cannot solve the complex life problems often associated with opioid use disorder, we need to increase access to all ORT forms so that patients do not feel they have to rush into any medication without adequate preparation.

AB - Background: Depot buprenorphine can potentially address many limitations of other forms of opioid replacement therapy (ORT). This paper builds upon the concept of the ‘informed patient’ to explore individuals’ decisions to initiate injectable depot buprenorphine. Methods: Data derive from a qualitative study of 26 people with opioid use disorder who were recruited from drug treatment services in England and Wales and interviewed within 72 hours of starting injectable depot buprenorphine treatment. Interviews were conducted by telephone, audio-recorded, transcribed verbatim, and analysed via Iterative Categorization. Findings: Participants’ decisions to initiate treatment were underpinned by receiving sufficient information to trust depot buprenorphine; current treatment not meeting their personal needs or goals; frequently uncritical perceptions of depot buprenorphine; and restricted access to depot buprenorphine making recipients feel grateful. Overall, participants said they had enough information and knowledge to decide they wanted depot buprenorphine. However, dissatisfaction with current ORT, desire for better treatment, and depot buprenorphine’s limited availability seemed to hinder informed decision-making. Conclusions: Whilst pharmaceutical products cannot solve the complex life problems often associated with opioid use disorder, we need to increase access to all ORT forms so that patients do not feel they have to rush into any medication without adequate preparation.

M3 - Article

SN - 0968-7637

JO - Drugs: Education, Prevention and Policy

JF - Drugs: Education, Prevention and Policy

ER -